Salubris Biotechnology Co. have reported the development of novel antibody-drug conjugates (ADCs) against glypican-3 (GPC3), an oncofetal glycoprotein overexpressed in approximately 70%-85% of hepatocellular carcinoma (HCC) cases but absent in normal adult tissues.